Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up.
Nelson Spector
Research Funding - Novartis
Brian Leber
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Jeffrey Howard Lipton
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Stock Ownership - ARIAD
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Research Funding - Bristol-Myers Squibb; Novartis
Carmino De Souza
Research Funding - Novartis
Beatriz Moiraghi
Consultant or Advisory Role - Bristol-Myers Squibb
Juan Luis Steegmann
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Anthony P. Schwarer
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Francisco Cervantes
Consultant or Advisory Role - Novartis; Pfizer; Sanofi
Honoraria - Bristol-Myers Squibb; Novartis
Timothy P. Hughes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis
Das Purkayastha
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
LaTonya R Collins
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Tomasz K. Szczudlo
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Delphine Rea
Honoraria - Novartis